Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older.
Jackson LA, Gurtman A, van Cleeff M, Frenck RW, Treanor J, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Jackson LA, et al. Among authors: frenck rw. Vaccine. 2013 Aug 2;31(35):3594-602. doi: 10.1016/j.vaccine.2013.04.084. Epub 2013 May 18. Vaccine. 2013. PMID: 23688525 Free article. Clinical Trial.
Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults.
Frenck RW Jr, Gurtman A, Rubino J, Smith W, van Cleeff M, Jayawardene D, Giardina PC, Emini EA, Gruber WC, Scott DA, Schmöle-Thoma B. Frenck RW Jr, et al. Clin Vaccine Immunol. 2012 Aug;19(8):1296-303. doi: 10.1128/CVI.00176-12. Epub 2012 Jun 27. Clin Vaccine Immunol. 2012. PMID: 22739693 Free PMC article. Clinical Trial.
Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age.
Greenberg RN, Gurtman A, Frenck RW, Strout C, Jansen KU, Trammel J, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Greenberg RN, et al. Among authors: frenck rw. Vaccine. 2014 Apr 25;32(20):2364-74. doi: 10.1016/j.vaccine.2014.02.002. Epub 2014 Mar 5. Vaccine. 2014. PMID: 24606865 Clinical Trial.
Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older.
Frenck RW Jr, Fiquet A, Gurtman A, van Cleeff M, Davis M, Rubino J, Smith W, Sundaraiyer V, Sidhu M, Emini EA, Gruber WC, Scott DA, Schmoele-Thoma B; B1851020 Study Group. Frenck RW Jr, et al. Vaccine. 2016 Jun 24;34(30):3454-62. doi: 10.1016/j.vaccine.2016.04.093. Epub 2016 May 5. Vaccine. 2016. PMID: 27155493 Clinical Trial.
Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: Results of a randomised trial.
Creech CB, Frenck RW Jr, Sheldon EA, Seiden DJ, Kankam MK, Zito ET, Girgenti D, Severs JM, Immermann FW, McNeil LK, Cooper D, Jansen KU, Gruber W, Eiden J, Anderson AS, Baber J. Creech CB, et al. Among authors: frenck rw jr. Vaccine. 2017 Jan 5;35(2):385-394. doi: 10.1016/j.vaccine.2016.11.032. Epub 2016 Nov 17. Vaccine. 2017. PMID: 27866765 Free article. Clinical Trial.
Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 study.
Frenck RW Jr, Creech CB, Sheldon EA, Seiden DJ, Kankam MK, Baber J, Zito E, Hubler R, Eiden J, Severs JM, Sebastian S, Nanra J, Jansen KU, Gruber WC, Anderson AS, Girgenti D. Frenck RW Jr, et al. Vaccine. 2017 Jan 5;35(2):375-384. doi: 10.1016/j.vaccine.2016.11.010. Epub 2016 Dec 1. Vaccine. 2017. PMID: 27916408 Free article. Clinical Trial.
Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults.
Frenck RW Jr, Belshe R, Brady RC, Winokur PL, Campbell JD, Treanor J, Hay CM, Dekker CL, Walter EB Jr, Cate TR, Edwards KM, Hill H, Wolff M, Leduc T, Tornieporth N. Frenck RW Jr, et al. Vaccine. 2011 Aug 5;29(34):5666-74. doi: 10.1016/j.vaccine.2011.06.010. Epub 2011 Jun 23. Vaccine. 2011. PMID: 21699951 Free PMC article. Clinical Trial.
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.
Walsh EE, Frenck RW Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, Fontes-Garfias C, Shi PY, Türeci Ö, Tompkins KR, Lyke KE, Raabe V, Dormitzer PR, Jansen KU, Şahin U, Gruber WC. Walsh EE, et al. Among authors: frenck rw jr. N Engl J Med. 2020 Dec 17;383(25):2439-2450. doi: 10.1056/NEJMoa2027906. Epub 2020 Oct 14. N Engl J Med. 2020. PMID: 33053279 Free PMC article. Clinical Trial.
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3.
Falsey AR, Frenck RW Jr, Walsh EE, Kitchin N, Absalon J, Gurtman A, Lockhart S, Bailey R, Swanson KA, Xu X, Koury K, Kalina W, Cooper D, Zou J, Xie X, Xia H, Türeci Ö, Lagkadinou E, Tompkins KR, Shi PY, Jansen KU, Şahin U, Dormitzer PR, Gruber WC. Falsey AR, et al. Among authors: frenck rw jr. N Engl J Med. 2021 Oct 21;385(17):1627-1629. doi: 10.1056/NEJMc2113468. Epub 2021 Sep 15. N Engl J Med. 2021. PMID: 34525276 Free PMC article. Clinical Trial. No abstract available.
138 results